Apoptosis of human melanoma cells induced by inhibition of B-RAF V600E involves preferential splicing of bimS

Cell Death and Disease

Volumn 1, Issue 9, 2010, Pages

  Jiang, C C ^a   Lai, F ^a   Tay, K H ^a   Croft, A ^a   Rizos, H ^b   Becker, T M ^b   Yang, F ^a   Liu, H ^a   Thorne, R F ^a   Hersey, P ^a   Zhang, X D ^a  

^a CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Apoptosis; B RAF inhibitors; B RAFV600E; BimS; Melanoma

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; BIM EL PROTEIN; BIM L PROTEIN; BIM PROTEIN; BIM S PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLX 4720; PROTEIN BCL 2; PROTEIN MCL 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; BCL 2 LIKE PROTEIN 11; BCL-2-LIKE PROTEIN 11; INDOLE DERIVATIVE; ISOPROTEIN; MEMBRANE PROTEIN; NUCLEAR PROTEIN; ONCOPROTEIN; PHOSPHOPROTEIN; PROTEIN KINASE INHIBITOR; SFRS6 PROTEIN, HUMAN; SULFONAMIDE;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; UPREGULATION; WILD TYPE; AMINO ACID SUBSTITUTION; DRUG ANTAGONISM; GENETICS; METABOLISM; MUTATION; RNA INTERFERENCE; RNA SPLICING; TUMOR CELL LINE;

AMINO ACID SUBSTITUTION; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; HUMANS; INDOLES; MELANOMA; MEMBRANE PROTEINS; MUTATION; NUCLEAR PROTEINS; PHOSPHOPROTEINS; PROTEIN ISOFORMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RNA INTERFERENCE; RNA SPLICING; RNA, MESSENGER; RNA, SMALL INTERFERING; SULFONAMIDES;

EID: 79951818357     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2010.48     Document Type: Article

References (39)

1. Flaherty KT, Puzanov I, Sosman J, Kim K, Ribas A, McArthur A et al. Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 2009; 27 Abstract 9000.
2. Chapman P, Puzanov I, Sosman J, Kim K, Ribas A, McArthur A et al. Early efficacy signal demonstrated in advanced melanoma in a phase I trial of the oncogenic BRAF-selective inhibitor PLX4032. Eur J Cancer Suppl 2009; 7: 5.
3. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954. (Pubitemid 34716871)
4. Platz A, Egyhazi S, Ringborg U, Hansson J. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol 2008; 1: 395-405.
5. Wellbrock C, Rana S, Paterson H, Pickersgill H, Brummelkamp T, Marais R. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS One 2008; 3: e2734.
6. Tsai J Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008; 105: 3041-3046. (Pubitemid 351723664)
7. Cragg MS, Jansen ES, Cook M, Harris C, Strasser A, Scott CL. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest 2008; 118: 3651-3659.
8. Wang YF, Jiang CC, Kiejda KA, Gillespie S, Zhang XD, Hersey P. Induction of apoptosis in human melanoma cells by inhibition of MEK is caspase independent, and is mediated by the Bcl-2 family members PUMA, Bim and Mcl-1. Clin Cancer Res 2007; 13: 4934-4942. (Pubitemid 47294802)
9. Panka DJ, Atkins MB, Mier JW. Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma. Clin Cancer Res 2006; 12: 2371s-2375s.
10. VanBrocklin MW, Verhaegen M, Soengas MS, Holmen SL. Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma. Cancer Res 2009; 69: 1985-1994.
11. Eisenmann KM, VanBrocklin MW, Staffend NA, Kitchen SM, Koo HM. Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad. Cancer Res 2003; 63: 8330-8337. (Pubitemid 37549486)
12. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17: 393-403. (Pubitemid 40193310)
13. Ley R, Ewings KE, Hadfield K, Cook SJ. Regulatory phosphorylation of Bim: sorting out the ERK from the JNK. Cell Death Differ 2005; 12: 1008-1104.
14. O'Connor L, Strasser A, O'Reilly LA, Hausmann G, Adams JM, Cory S et al. Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J 1998; 17: 384-395. (Pubitemid 28045479)
15. Puthalakath H, Huang DC, O'Reilly LA, King SM, Strasser A. The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol Cell 1999; 3: 287-296. (Pubitemid 29290669)
16. Bouillet P, Zhang LC, Huang DC, Webb GC, Bottema CD, Shore P et al. Gene structure alternative splicing, and chromosomal localization of pro-apoptotic Bcl-2 relative Bim. Mamm Genome 2001; 12: 163-168. (Pubitemid 32147673)
17. Weber A, Paschen SA, Heger K, Wilfling F, Frankenberg T, Bauerschmitt H et al. BimSinduced apoptosis requires mitochondrial localization but not interaction with anti-apoptotic Bcl-2 proteins. J Cell Biol 2007; 177: 625-36. (Pubitemid 46799834)
18. Chen M, Manley JL. Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nat Rev Mol Cell Biol 2009; 10: 741-754.
19. Pajares MJ, Ezponda T, Catena R, Calvo A, Pio R, Montuenga LM. Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol 2007; 8: 349-357. (Pubitemid 46464532)
20. Schwerk C, Schulze-Osthoff K. Regulation of apoptosis by alternative pre-mRNA splicing. Mol Cell 2005; 19: 1-13. (Pubitemid 40884653)
21. Revil T, Shkreta L, Chabot B. Pre-mRNA alternative splicing in cancer: functional impact, molecular mechanisms and therapeutic perspectives. Bull Cancer 2006; 93: 909-919. (Pubitemid 44520873)
22. van Alphen RJ, Wiemer EA, Burger H, Eskens FA. The spliceosome as target for anticancer treatment. Br J Cancer 2009; 100: 228-232.
23. Venables JP. Aberrant and alternative splicing in cancer. Cancer Res 2004; 64: 7647-7654. (Pubitemid 39446889)
24. Kirschbaum-Slager N, Lopes GM, Galante PA, Riggins GJ, de Souza SJ. Splicing factors are differentially expressed in tumors. Genet Mol Res 2004; 3: 512-520. (Pubitemid 40318045)
25. Shepard PJ, Hertel KJ. The SR protein family. Genome Biol 2009; 10: 242.
26. Blaustein M, Pelisch F, Srebrow A. Signals, pathways and splicing regulation. Int J Biochem Cell Biol 2007; 39: 2031-2048. (Pubitemid 47376826)
27. Adams JM, Cory S. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol 2007; 19: 488-496. (Pubitemid 47487452)
28. Zhang XD, Gillespie SK, Borrow JM, Hersey P. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol Cancer Ther 2004; 3: 425-435. (Pubitemid 39193720)
29. Johansson P, Pavey S, Hayward N. Confirmation of a BRAF mutation-associated gene expression signature in melanoma. Pigment Cell Res 2007; 20: 216-221. (Pubitemid 46776377)
30. Cartlidge RA, Thomas GR, Cagnol S, Jong KA, Molton SA, Finch AJ et al. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. Pigment Cell Melanoma Res 2008; 21: 534-544.
31. Dai DL, Wang Y, Liu M, Martinka M, Li G. Bim expression is reduced in human cutaneous melanomas. J Invest Dermatol 2008; 128: 403-407.
32. Park JW, Graveley BR. Complex alternative splicing. Adv Exp Med Biol 2007; 623: 50-63.
33. Matter N, Herrlich P, König H. Signal-dependent regulation of splicing via phosphorylation of Sam68. Nature 2002; 420: 691-695. (Pubitemid 36764503)
34. Patel NA, Kaneko S, Apostolatos HS, Bae SS, Watson JE, Davidowitz K et al. Molecular and genetic studies imply Akt-mediated signaling promotes protein kinase CbetaII alternative splicing via phosphorylation of serine/arginine-rich splicing factor SRp40. J Biol Chem 2005; 280: 14302-14309. (Pubitemid 40517333)
35. Weg-Remers S, Ponta H, Herrlich P, König H. Regulation of alternative pre-mRNA splicing by the ERK MAP-kinase pathway. EMBO J 2001; 20: 4194-4203. (Pubitemid 32751835)
36. Wang YF, Jiang CC, Kiejda KA, Gillespie S, Zhang XD, Hersey P. Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. Clin Cancer Res 2007; 13: 4934-4942. (Pubitemid 47294802)
37. Jiang CC, Chen LH, Gillespie S, Wang YF, Kiejda KA, Zhang XD et al. Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosis. Cancer Res 2007; 67: 9750-9761. (Pubitemid 47621222)
38. Liu H, Jiang CC, Lavis CJ, Croft A, Dong L, Tseng HY et al. 2-Deoxy-D-glucose enhances TRAIL-induced apoptosis in human melanoma cells through XBP-1-mediated up-regulation of TRAIL-R2. Mol Cancer 2009; 8: 122.
39. Jiang CC, Wroblewski D, Yang F, Hersey P, Zhang XD. Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax. Neoplasia 2009; 11: 945-955.